Medtronic Q3 FY2022 revenue flat at $7.8B; GAAP EPS $1.10 (+17%), non-GAAP EPS $1.37 (+6%)

Medtronic plc

2022-Q3 EPS reported $2.63 revenue$23,597,000,000

Revenue $7.763B flat YoY; organic growth 2%; COVID-19 impact on U.S. procedure volumes.
GAAP diluted EPS $1.10 (+17%); non-GAAP diluted EPS $1.37 (+6%), a penny above consensus.
Q4 guidance: organic revenue growth ~5.5%; non-GAAP EPS $1.56-$1.58.
Diabetes segment revenue down 7% as reported (-5% organic) driven by U.S. declines.
Cardiovascular up 3% organic; Medical Surgical up 1% organic; Neuroscience up 2% organic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.